Open Access

Synergistic protection of bone vasculature and bone mass by desferrioxamine in osteoporotic mice

  • Authors:
    • Liang Wang
    • Peng Jia
    • Yu Shan
    • Yanming Hao
    • Xiao Wang
    • Yu Jiang
    • Ye Yuan
    • Qiaoqiao Du
    • Hui Zhang
    • Fan Yang
    • Wen Zhang
    • Mao Sheng
    • Youjia Xu
  • View Affiliations

  • Published online on: September 8, 2017     https://doi.org/10.3892/mmr.2017.7451
  • Pages: 6642-6649
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

It has previously been demonstrated that impaired angiogenesis is associated with metabolic abnormalities in bone in addition to osteoporosis (including postmenopausal osteoporosis). Enhancing vessel formation in bone is therefore a potential clinical therapy for osteoporosis. The present study conducted an in‑depth investigation using desferrioxamine (DFO) in an ovariectomy (OVX)‑induced osteoporotic mouse model in order to determine the time frame of alteration of bone characteristics and the therapeutic effect of DFO. It was demonstrated that OVX induced instant bone mass loss 1 week following surgery, as expected. In contrast, DFO treatment protected the mice against OVX‑induced osteoporosis during the first week, however failed to achieve long‑term protection at a later stage. A parallel alteration for cluster of differentiation 31/endomucin double positive vessels (type H vessels) was observed, which have previously been reported to be associated with osteogenesis. DFO administration not only partially prevented bone loss and maintained trabecular bone microarchitecture, however additionally enhanced the type H vessels during the first week post‑OVX. The molecular mechanism of how DFO influences type H vessels to regulate bone metabolism needs to be further investigated. However, the findings of the present study provide preliminary evidence to support combined vascular and osseous therapies for osteoporotic patients. Pharmacotherapy may offer a novel target for improving osteoporosis by promoting type H vessel formation, which indicates potential clinical significance in the field of bone metabolism.
View Figures
View References

Related Articles

Journal Cover

November-2017
Volume 16 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang L, Jia P, Shan Y, Hao Y, Wang X, Jiang Y, Yuan Y, Du Q, Zhang H, Yang F, Yang F, et al: Synergistic protection of bone vasculature and bone mass by desferrioxamine in osteoporotic mice. Mol Med Rep 16: 6642-6649, 2017
APA
Wang, L., Jia, P., Shan, Y., Hao, Y., Wang, X., Jiang, Y. ... Xu, Y. (2017). Synergistic protection of bone vasculature and bone mass by desferrioxamine in osteoporotic mice. Molecular Medicine Reports, 16, 6642-6649. https://doi.org/10.3892/mmr.2017.7451
MLA
Wang, L., Jia, P., Shan, Y., Hao, Y., Wang, X., Jiang, Y., Yuan, Y., Du, Q., Zhang, H., Yang, F., Zhang, W., Sheng, M., Xu, Y."Synergistic protection of bone vasculature and bone mass by desferrioxamine in osteoporotic mice". Molecular Medicine Reports 16.5 (2017): 6642-6649.
Chicago
Wang, L., Jia, P., Shan, Y., Hao, Y., Wang, X., Jiang, Y., Yuan, Y., Du, Q., Zhang, H., Yang, F., Zhang, W., Sheng, M., Xu, Y."Synergistic protection of bone vasculature and bone mass by desferrioxamine in osteoporotic mice". Molecular Medicine Reports 16, no. 5 (2017): 6642-6649. https://doi.org/10.3892/mmr.2017.7451